Formulation and Evaluation of Nanoparticles of Poorly Soluble Anti Diabetic Drug

Abstract

Diabetes mellitus, a pervasive metabolic disorder, imposes a substantial global health burden, with Type 2 Diabetes (T2D) being a prevalent form characterized by insulin resistance and impaired glucose metabolism. The conventional treatment often involves oral anti-diabetic medications, such as Pioglitazone (PGZ). However, the challenges of poor water solubility inherent in PGZ necessitate innovative solutions. Nanoparticle-based drug delivery systems present a promising avenue for enhancing solubility and bioavailability. newlineThis research focuses on encapsulating PGZ within nanoparticles to achieve controlled drug release, targeted delivery, and improved therapeutic outcomes. The study outlines primary objectives, including the formulation and optimization of PGZ-loaded nanoparticles and the evaluation of enhanced bioavailability. By leveraging nanotechnology and building upon established research in diabetes management, this study explores the potential implications for T2D treatment. newlineThe experimental approach involves nanogrinding PGZ using a nanosuspension precipitation method. Stabilizing effects of Tween 80 Emulsifier surface active agents are investigated, with formulation factors and process parameters meticulously examined. The study evaluates the ratio of polymer to drug, milling time, and concentration of PGZ beads, while different concentrations of surfactants, such as Tween 80 and ethanol: distilled water, are explored for nanosuspension preparation. Responses measured include particle size, zeta potential, and Yield Percentage. newlineThe outcomes of this research hold promise for revolutionizing PGZ therapy, offering a pathway to enhance solubility and bioavailability. The potential benefits include improved therapeutic efficacy, dose reduction, enhanced patient compliance, and targeted drug delivery. This study contributes to the broader landscape of diabetes research, striving towards enhancing patient outcomes and quality of life in the management of Type 2 Diabetes. newline